shutterstock_1201562074_designer491

designer491 / Shutterstock.com

24 December 2019Big PharmaSarah Morgan

Sandoz and Momenta to pay $120m to end antitrust suit

Sandoz and Momenta have agreed to pay $120 million to bring an antitrust class action over blockbuster blood clot drug enoxaparin to an end.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Judge approves $120m Momenta and Sandoz settlement

6 January 2020 A US federal judge has given preliminary approval to the proposed settlement in the class action suit led by Nashville General Hospital against Momenta Pharmaceuticals and Sandoz over their alleged manipulation of drug testing protocols.

Momenta to pay $35m to end enoxaparin class-action suit

12 December 2019 Momenta Pharmaceuticals has agreed to pay $35 million to settle a 2015 class-action suit that claimed that it blocked generics of the blockbuster blood clot drug enoxaparin from coming to market.

More on this story

Judge approves $120m Momenta and Sandoz settlement

6 January 2020 A US federal judge has given preliminary approval to the proposed settlement in the class action suit led by Nashville General Hospital against Momenta Pharmaceuticals and Sandoz over their alleged manipulation of drug testing protocols.

Momenta to pay $35m to end enoxaparin class-action suit

12 December 2019 Momenta Pharmaceuticals has agreed to pay $35 million to settle a 2015 class-action suit that claimed that it blocked generics of the blockbuster blood clot drug enoxaparin from coming to market.

More on this story

Judge approves $120m Momenta and Sandoz settlement

6 January 2020 A US federal judge has given preliminary approval to the proposed settlement in the class action suit led by Nashville General Hospital against Momenta Pharmaceuticals and Sandoz over their alleged manipulation of drug testing protocols.

Momenta to pay $35m to end enoxaparin class-action suit

12 December 2019 Momenta Pharmaceuticals has agreed to pay $35 million to settle a 2015 class-action suit that claimed that it blocked generics of the blockbuster blood clot drug enoxaparin from coming to market.

More features

Novartis moves to block cancer drug generic in US

WATCH: China patent landscape—AI, patent linkage, export controls, and more

China bars USPTO employee from leaving country

UPC hands rare default win to Insulet, bans insulin pump in EU

GSK loses appeal over purple inhaler TM in Europe

Astellas defends Xtandi patent as court rejects generics’ appeal

Jury sides with Allergan in $56M Botox tech feud

Novartis fails latest bid to block Entresto copies